Featured Research

from universities, journals, and other organizations

Prostate Cancer Research May Be Faster With PSA Endpoints

Date:
April 19, 2006
Source:
Columbia University Medical Center
Summary:
A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival. Researchers looking to speed up the process of clinical trials have suggested that these biomarkers could be used to measure treatment efficacy.

A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival. Researchers looking to speed up the process of clinical trials have suggested that these biomarkers could be used to measure treatment efficacy.

Currently, the U.S. Food and Drug Administration accepts only survival as an endpoint of measure. Survival as a primary endpoint was used in phase III studies of novel chemotherapeutic drugs for men with androgen-independent prostate.

Daniel P. Petrylak, M.D., associate professor of medicine at Columbia University College of Physicians & Surgeons and director of the genitourinary oncology program at NewYork-Presbyterian/Columbia, together with his research team, retrospectively analyzed results of 551 men with prostate cancer treated in the Southwest Oncology Group Protocol S9916. By reviewing the clinical trial, it was noted that there were several different changes in PSA levels, which could possibly serve as surrogate endpoints for survival.

The authors observed that the risk of death, in men whose serum PSA levels declined by at least 30 percent in the first three months of treatment, was reduced more than 50 percent. Findings are published in the Journal of the National Cancer Institute (April 19, 2006 issue).

"The findings show that PSA levels can be a reliable endpoint measure of prostate cancer treatment efficacy," said Dr. Petrylak, lead investigator. "However, this and other candidate surrogate endpoints must be validated in independent clinical trials of men with prostate cancer."

This study is a follow-up to a landmark phase III trial published in the New England Journal of Medicine (Oct. 7, 2004), by the same Columbia University Medical Center and NewYork-Presbyterian Hospital/Columbia research team, who are members of SWOG, one of the largest cancer clinical trials cooperative groups in the United States. The study found that men with androgen-independent (hormone-refractory) metastatic prostate cancer who were treated with the chemotherapy drug Taxotereฎ (docetaxel) Injection Concentrate in combination with the drug estramustine survived 20 percent longer than similar patients receiving the standard therapy.

Prostate cancer is the second leading cause of cancer death in men. One in six men will likely develop prostate cancer within their lifetime. The American Cancer Society estimates there were about 232,090 new cases of prostate cancer in the United States in 2005. About 30,350 men will die of the disease this year alone.

 


Story Source:

The above story is based on materials provided by Columbia University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Columbia University Medical Center. "Prostate Cancer Research May Be Faster With PSA Endpoints." ScienceDaily. ScienceDaily, 19 April 2006. <www.sciencedaily.com/releases/2006/04/060419073302.htm>.
Columbia University Medical Center. (2006, April 19). Prostate Cancer Research May Be Faster With PSA Endpoints. ScienceDaily. Retrieved April 24, 2014 from www.sciencedaily.com/releases/2006/04/060419073302.htm
Columbia University Medical Center. "Prostate Cancer Research May Be Faster With PSA Endpoints." ScienceDaily. www.sciencedaily.com/releases/2006/04/060419073302.htm (accessed April 24, 2014).

Share This



More Health & Medicine News

Thursday, April 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Fungus Killing Bats, Spreading in US

Deadly Fungus Killing Bats, Spreading in US

AP (Apr. 24, 2014) — A disease that has killed more than six million cave-dwelling bats in the United States is on the move and wildlife biologists are worried. White Nose Syndrome, discovered in New York in 2006, has now spread to 25 states. (April 24) Video provided by AP
Powered by NewsLook.com
Companies Ramp Up Wellness to Lower Health Costs

Companies Ramp Up Wellness to Lower Health Costs

AP (Apr. 24, 2014) — That little voice telling you to exercise, get in shape and get healthy is probably coming from your boss. More companies are beefing up wellness programs to try and cut down their health care costs. (April 24) Video provided by AP
Powered by NewsLook.com
Blood From World's Oldest Woman Suggests Life Limit

Blood From World's Oldest Woman Suggests Life Limit

Newsy (Apr. 24, 2014) — Scientists say for the extremely elderly, their stem cells might reach a state of exhaustion. This could limit one's life span. Video provided by Newsy
Powered by NewsLook.com
FDA Wants To Ban Sales Of E-Cigarettes To Minors

FDA Wants To Ban Sales Of E-Cigarettes To Minors

Newsy (Apr. 24, 2014) — The Food and Drug Administration wants to crack down on the use of e-cigarettes, banning the sale of the product to minors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins